CELLTOP Clinical Trial: First Report From a Phase 1 Trial of Autologous Adipose Tissue –Derived Mesenchymal Stem Cells in the Treatment of Paralysis Due to Traumatic Spinal Cord Injury

Spinal cord injury (SCI) is a devastating condition with limited pharmacological treatment options to restore function. Regenerative approaches have recently attracted interest as an adjuvant to current standard of care. Adipose tissue –derived (AD) mesenchymal stem cells (MSCs) represent a readily accessible cell source with high proliferative capacity. The CELLTOP study, an ongoing multidisciplinary phase 1 clinical trial conducted at Mayo Clinic (ClinicalTrials.gov Identifier: NCT03308565), is investigating the safety and eff icacy of intrathecal autologous AD-MSCs in patients with blunt, traumatic SCI.

Source: Mayo Clinic Proceedings - November 26, 2019 Category: Internal Medicine Authors: Mohamad Bydon, Allan B. Dietz, Sandy Goncalves, F M Moinuddin, Mohammed Ali Alvi, Anshit Goyal, Yagiz Yolcu, Christine L. Hunt, Kristin L. Garlanger, Ronald K. Reeves, Andre Terzic, Anthony J. Windebank, Wenchun Qu Tags: Case report Source Type: research